WO1998006850A1 - Immunologisch aktive proteine von borrelia burgdorferi, dafür kodierende nukleinsäuren sowie deren verwendung in testkits und als impfstoffe - Google Patents
Immunologisch aktive proteine von borrelia burgdorferi, dafür kodierende nukleinsäuren sowie deren verwendung in testkits und als impfstoffe Download PDFInfo
- Publication number
- WO1998006850A1 WO1998006850A1 PCT/EP1997/004215 EP9704215W WO9806850A1 WO 1998006850 A1 WO1998006850 A1 WO 1998006850A1 EP 9704215 W EP9704215 W EP 9704215W WO 9806850 A1 WO9806850 A1 WO 9806850A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- sequence
- immunologically active
- test kit
- partial sequence
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 94
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 88
- 241000589969 Borreliella burgdorferi Species 0.000 title claims abstract description 27
- 229960005486 vaccine Drugs 0.000 title claims description 14
- 238000003149 assay kit Methods 0.000 title description 10
- 239000002253 acid Substances 0.000 title 1
- 150000007513 acids Chemical class 0.000 title 1
- 150000001413 amino acids Chemical class 0.000 claims abstract description 38
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 4
- 238000012360 testing method Methods 0.000 claims description 27
- 150000007523 nucleic acids Chemical class 0.000 claims description 20
- 108020004707 nucleic acids Proteins 0.000 claims description 17
- 102000039446 nucleic acids Human genes 0.000 claims description 17
- 208000015181 infectious disease Diseases 0.000 claims description 14
- 102000004190 Enzymes Human genes 0.000 claims description 12
- 108090000790 Enzymes Proteins 0.000 claims description 12
- 238000006243 chemical reaction Methods 0.000 claims description 11
- 208000016604 Lyme disease Diseases 0.000 claims description 10
- 238000001514 detection method Methods 0.000 claims description 8
- 239000002773 nucleotide Substances 0.000 claims description 8
- 125000003729 nucleotide group Chemical group 0.000 claims description 8
- 238000003752 polymerase chain reaction Methods 0.000 claims description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 238000001262 western blot Methods 0.000 claims description 6
- 241000894006 Bacteria Species 0.000 claims description 5
- 241000589968 Borrelia Species 0.000 claims description 5
- 108060003951 Immunoglobulin Proteins 0.000 claims description 4
- 102000018358 immunoglobulin Human genes 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 108040007629 peroxidase activity proteins Proteins 0.000 claims description 4
- 108090001008 Avidin Proteins 0.000 claims description 3
- 238000011238 DNA vaccination Methods 0.000 claims description 2
- 108010090804 Streptavidin Proteins 0.000 claims description 2
- 102000003992 Peroxidases Human genes 0.000 claims 1
- 239000000427 antigen Substances 0.000 description 33
- 102000036639 antigens Human genes 0.000 description 33
- 108091007433 antigens Proteins 0.000 description 33
- 108090000765 processed proteins & peptides Proteins 0.000 description 28
- 102000004196 processed proteins & peptides Human genes 0.000 description 21
- 239000000499 gel Substances 0.000 description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 239000013615 primer Substances 0.000 description 14
- 108020004414 DNA Proteins 0.000 description 12
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 11
- 239000000872 buffer Substances 0.000 description 10
- 239000012634 fragment Substances 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 6
- 239000000020 Nitrocellulose Substances 0.000 description 6
- 229920001220 nitrocellulos Polymers 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000009396 hybridization Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000010353 genetic engineering Methods 0.000 description 4
- 238000003119 immunoblot Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 108700023315 OspC Proteins 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 102000013415 peroxidase activity proteins Human genes 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 241000238876 Acari Species 0.000 description 2
- 206010061591 Borrelia infection Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- ZRKLEAHGBNDKHM-UHFFFAOYSA-N N,n'-diallyl-2,3-dihydroxysuccinamide Chemical compound C=CCNC(=O)C(O)C(O)C(=O)NCC=C ZRKLEAHGBNDKHM-UHFFFAOYSA-N 0.000 description 2
- 208000008457 Neurologic Manifestations Diseases 0.000 description 2
- 108700006640 OspA Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 239000006180 TBST buffer Substances 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 239000013024 dilution buffer Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 206010062746 Carditis Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 238000011537 Coomassie blue staining Methods 0.000 description 1
- 229920002271 DEAE-Sepharose Polymers 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 108010040721 Flagellin Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 101710118538 Protease Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108010034546 Serratia marcescens nuclease Proteins 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000589884 Treponema pallidum Species 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- VFNGKCDDZUSWLR-UHFFFAOYSA-N disulfuric acid Chemical compound OS(=O)(=O)OS(O)(=O)=O VFNGKCDDZUSWLR-UHFFFAOYSA-N 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 208000021646 inflammation of heart layer Diseases 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 201000004614 iritis Diseases 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 230000007775 late Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- CGVLVOOFCGWBCS-RGDJUOJXSA-N n-octyl β-d-thioglucopyranoside Chemical compound CCCCCCCCS[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CGVLVOOFCGWBCS-RGDJUOJXSA-N 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- -1 plOO Proteins 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 208000016523 tick-borne infectious disease Diseases 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT97935563T ATE291088T1 (de) | 1996-08-14 | 1997-08-01 | Immunologisch aktive proteine von borrelia burgdorferi, dafür kodierende nukleinsäuren sowie deren verwendung in testkits und als impfstoffe |
AU38509/97A AU3850997A (en) | 1996-08-14 | 1997-08-01 | Immunologically active proteins of borrelia burgdorferi, coded nuclein acids of such and their use in test kits and vaccines |
CA2263152A CA2263152C (en) | 1996-08-14 | 1997-08-01 | Immunologically active proteins from borrelia burgdorferi, nucleic acids which encode them, and their use in test kits and as vaccines |
EP97935563A EP0918865B1 (de) | 1996-08-14 | 1997-08-01 | Immunologisch aktive proteine von borrelia burgdorferi, dafür kodierende nukleinsäuren sowie deren verwendung in testkits und als impfstoffe |
DE59712235T DE59712235D1 (de) | 1996-08-14 | 1997-08-01 | Immunologisch aktive proteine von borrelia burgdorferi, dafür kodierende nukleinsäuren sowie deren verwendung in testkits und als impfstoffe |
US09/242,299 US6610301B1 (en) | 1996-08-14 | 1997-08-01 | Immunologically active proteins from Borrelia burgdorferi, nucleic acids which encode them, and their use in test kits and as vaccines |
DK97935563T DK0918865T3 (da) | 1996-08-14 | 1997-08-01 | Immunologisk aktive proteiner af Borrelia burgdorferi, derfor kodende nukleinsyrer samt deres anvendelse i testkits og som vacciner |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19632862.4 | 1996-08-14 | ||
DE19632862A DE19632862B4 (de) | 1996-08-14 | 1996-08-14 | Immunologisch aktive Proteine von Borrelia burgdorferi, dafür kodierende Nukleinsäuren sowie deren Verwendung in Testkits und als Impfstoffe |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/242,299 A-371-Of-International US6610301B1 (en) | 1996-08-14 | 1997-08-01 | Immunologically active proteins from Borrelia burgdorferi, nucleic acids which encode them, and their use in test kits and as vaccines |
US10/403,220 Division US6808711B2 (en) | 1996-08-14 | 2003-03-26 | Immunologically active proteins from Borrelia burgdorferi, nucleic acids which encode them, and their use in test kits and as vaccines |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998006850A1 true WO1998006850A1 (de) | 1998-02-19 |
Family
ID=7802674
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1997/004215 WO1998006850A1 (de) | 1996-08-14 | 1997-08-01 | Immunologisch aktive proteine von borrelia burgdorferi, dafür kodierende nukleinsäuren sowie deren verwendung in testkits und als impfstoffe |
Country Status (8)
Country | Link |
---|---|
US (2) | US6610301B1 (de) |
EP (1) | EP0918865B1 (de) |
AT (1) | ATE291088T1 (de) |
AU (1) | AU3850997A (de) |
CA (1) | CA2263152C (de) |
DE (2) | DE19632862B4 (de) |
DK (1) | DK0918865T3 (de) |
WO (1) | WO1998006850A1 (de) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000021989A1 (en) * | 1998-10-09 | 2000-04-20 | Medimmune, Inc. | Decorin binding proteins dbp a and b and genes encoding them |
US6214355B1 (en) * | 1995-04-24 | 2001-04-10 | Texas A & M University System | DbpA compositions |
US6228835B1 (en) | 1995-04-24 | 2001-05-08 | The Texas A & M Unversity System | Decorin binding protein compositions |
US6248517B1 (en) | 1995-04-24 | 2001-06-19 | The Texas A & M University System | Decorin binding protein compositions and methods of use |
US6312907B1 (en) | 1995-04-24 | 2001-11-06 | The Texas A & M University System | DbpA compositions and methods of use |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE301716T1 (de) | 1996-02-21 | 2005-08-15 | Univ Texas | Vmp-ähnliche sequenzen von pathogener borrelia |
ATE337335T1 (de) * | 1997-06-30 | 2006-09-15 | Univ Tulane | Oberflächenantigene und proteine für zusammensetzungen zu diagnose und vorbeugung der lyme-kkrankheit |
AU5495500A (en) * | 1999-06-16 | 2001-01-02 | The Texas A & M University System | Decorin binding protein essential peptides and methods of use |
US6517838B1 (en) | 2000-06-16 | 2003-02-11 | The Texas A&M University System | Decorin binding protein essential peptides and methods of use |
AU2003299872A1 (en) | 2002-12-20 | 2004-07-22 | Board Of Regents, The University Of Texas System | Vmp-like sequences of pathogenic borrelia species and strains |
FR2949472B1 (fr) * | 2009-08-28 | 2013-08-09 | Biomerieux Sa | Proteines utilisees pour le diagnostic d'une borreliose de lyme |
FR2949473B1 (fr) | 2009-08-28 | 2013-08-09 | Biomerieux Sa | Proteines utilisees pour le diagnostic d'une borreliose de lyme |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996034106A1 (en) * | 1995-04-24 | 1996-10-31 | The Texas A & M University System | Decorin binding protein compositions and methods of use |
WO1997027301A1 (en) * | 1996-01-22 | 1997-07-31 | The Texas A & M University System | Decorin binding protein compositions and methods of use |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6054296A (en) * | 1988-10-24 | 2000-04-25 | Symbicom Ab | 66 kDa antigen from Borrelia |
DK590288D0 (da) * | 1988-10-24 | 1988-10-24 | Symbicom Ab | Kemiske forbindelser |
US5246844A (en) * | 1991-10-22 | 1993-09-21 | Board Of Regents, The University Of Texas System | Virulence associated proteins in borrelia burgdorferi (bb) |
US5279938A (en) * | 1989-06-05 | 1994-01-18 | The United States Of America As Represented By The Department Of Health And Human Services | Sensitive diagnostic test for lyme disease |
DE4015911A1 (de) * | 1989-09-19 | 1991-03-28 | Max Planck Gesellschaft | Impfstoff gegen die lyme-krankheit |
DE4018988C2 (de) * | 1990-06-13 | 1999-07-08 | Mikrogen Molekularbiol Entw | Immunologisch aktive Proteine von Borrelia burgdorferi, Testkits, die diese Proteine enthalten und zum Nachweis von Antikörpern in Untersuchungsflüssigkeiten geeignet sind, monoklonale Antikörper, die gegen die immunologisch aktiven Proteine gerichtet sind und die Verwendung dieser Proteine als Impfstoffe gegen durch Borrelia-Stämme hervorgerufene Infektionen |
DE3942728C1 (en) * | 1989-12-22 | 1991-05-23 | Mikrogen Molekularbiologische Entwicklungs-Gmbh, 8000 Muenchen, De | New immunologically active proteins derived from Borelia burgdorferiensity polyethylene vessel and a high density polyethylene sealing cap - useful as vaccine and for quick accurate diagnosis of Borelia infections |
US5470712A (en) * | 1990-03-05 | 1995-11-28 | Us Health | Antigenic proteins of Borrelia burgdorferi |
ATE142888T1 (de) * | 1990-03-05 | 1996-10-15 | Us Health | Antigen-wirkende proteine von borrelia burgdorferi |
JPH07501687A (ja) * | 1991-08-15 | 1995-02-23 | スミスクライン・ビーチャム・バイオロジカルス(ソシエテ・アノニム) | ボレリア・ブルグドルフェリのサブグループのosp a 蛋白、それをコードしている遺伝子およびワクチン |
EP0540457A1 (de) * | 1991-10-22 | 1993-05-05 | Symbicom Ab | Verbesserungen der Diagnose und der Prophylaxe von Borrelia burgdorferi |
BE1006728A3 (fr) * | 1993-02-19 | 1994-11-29 | Wallone Region | Sondes d'acides nucleiques specifiques au spirochete borrelia burgdorferi. |
AU6366894A (en) * | 1993-03-11 | 1994-09-26 | Regents Of The University Of California, The | Methods, compositions, and kits for diagnosing lyme disease |
US5656451A (en) * | 1993-07-30 | 1997-08-12 | Yale University | OspE, OspF, and S1 polypeptides in borrelia burgdorferi |
GB9320317D0 (en) * | 1993-10-01 | 1993-11-17 | Max Planck Gesellschaft | Vaccines and diagnostics |
AU8127494A (en) * | 1993-11-01 | 1995-05-23 | Associated Universities, Inc. | Chimeric proteins comprising borrelia polypeptides: uses therefor |
CZ42497A3 (en) * | 1994-08-17 | 1997-10-15 | Max Planck Gesellschaft | VACCINE CONTAINING BORRELIA BURGDORFERI OspG |
-
1996
- 1996-08-14 DE DE19632862A patent/DE19632862B4/de not_active Expired - Lifetime
-
1997
- 1997-08-01 DK DK97935563T patent/DK0918865T3/da active
- 1997-08-01 CA CA2263152A patent/CA2263152C/en not_active Expired - Lifetime
- 1997-08-01 AU AU38509/97A patent/AU3850997A/en not_active Abandoned
- 1997-08-01 AT AT97935563T patent/ATE291088T1/de active
- 1997-08-01 WO PCT/EP1997/004215 patent/WO1998006850A1/de active IP Right Grant
- 1997-08-01 US US09/242,299 patent/US6610301B1/en not_active Expired - Lifetime
- 1997-08-01 EP EP97935563A patent/EP0918865B1/de not_active Expired - Lifetime
- 1997-08-01 DE DE59712235T patent/DE59712235D1/de not_active Expired - Lifetime
-
2003
- 2003-03-26 US US10/403,220 patent/US6808711B2/en not_active Expired - Lifetime
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996034106A1 (en) * | 1995-04-24 | 1996-10-31 | The Texas A & M University System | Decorin binding protein compositions and methods of use |
WO1997027301A1 (en) * | 1996-01-22 | 1997-07-31 | The Texas A & M University System | Decorin binding protein compositions and methods of use |
Non-Patent Citations (2)
Title |
---|
GUO B ET AL: "Identification of decorin binding proteins on the outer membrane surface of Borrelia burgdorferi", ABSTRACTS OF THE GENERAL MEETING OF THE AMERICAN SOCIETY FOR MICROBIOLOGY, 94 (0). MAI 1994. 124., XP002012437 * |
GUO B P ET AL: "EVIDENCE THAT THE DECORIN BINDING PROTEIN OF BORRELIA BURGDORFERI IS AN ADHESIN", ABSTRACTS OF THE GENERAL MEETING OF THE AMERICAN SOCIETY FOR MICROBIOLOGY, vol. 96, May 1996 (1996-05-01), pages 248, XP000618881 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6214355B1 (en) * | 1995-04-24 | 2001-04-10 | Texas A & M University System | DbpA compositions |
US6228835B1 (en) | 1995-04-24 | 2001-05-08 | The Texas A & M Unversity System | Decorin binding protein compositions |
US6248517B1 (en) | 1995-04-24 | 2001-06-19 | The Texas A & M University System | Decorin binding protein compositions and methods of use |
US6312907B1 (en) | 1995-04-24 | 2001-11-06 | The Texas A & M University System | DbpA compositions and methods of use |
WO2000021989A1 (en) * | 1998-10-09 | 2000-04-20 | Medimmune, Inc. | Decorin binding proteins dbp a and b and genes encoding them |
Also Published As
Publication number | Publication date |
---|---|
EP0918865A1 (de) | 1999-06-02 |
DE59712235D1 (de) | 2005-04-21 |
DK0918865T3 (da) | 2005-05-30 |
US6610301B1 (en) | 2003-08-26 |
US6808711B2 (en) | 2004-10-26 |
US20030185859A1 (en) | 2003-10-02 |
DE19632862B4 (de) | 2006-08-03 |
CA2263152C (en) | 2010-07-27 |
DE19632862A1 (de) | 1998-02-19 |
ATE291088T1 (de) | 2005-04-15 |
AU3850997A (en) | 1998-03-06 |
CA2263152A1 (en) | 1998-02-19 |
EP0918865B1 (de) | 2005-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0506868B2 (de) | Immunologisch aktive proteine von borrelia burgdorferi, zusammenhängende testkits und impfstoff | |
DE69835756T2 (de) | Hiv-1 tat und/oder nef enthaltende fusionsproteine | |
DE68929550T2 (de) | Im Wesentlichen reines ganzes OspaA-Protein, frei von anderen B. burgdorferi-Materialien | |
DE3588248T2 (de) | LAV-Antigene und -Peptide | |
DE68929467T2 (de) | HIV-2 Varianten | |
DE69220042T3 (de) | Mycobakterium polypeptide und dafür kodierende nukleinsäuren zur diagnose und kontrolle von tuberkulose | |
DE69433690T2 (de) | Chimere proteine, welche borrelia polypeptide beinhalten, verwendungen dafür | |
CH676004A5 (de) | ||
US5571718A (en) | Cloning and expression of soluble truncated variants of Borrelia OspA, OspB and Vmp7 | |
WO1988005823A2 (en) | Mycobacterium tuberculosis genes encoding protein antigens | |
WO1998006850A1 (de) | Immunologisch aktive proteine von borrelia burgdorferi, dafür kodierende nukleinsäuren sowie deren verwendung in testkits und als impfstoffe | |
DE69628336T2 (de) | Behandlung und diagnose helicobacter pylori infektionen | |
EP2149051B1 (de) | Verfahren und immunabsorbentien zur spezifischen detektion und absorption zöliakie- und dermatitis herpetiformis assoziierter antikörper | |
EP0617128A1 (de) | Rekombinanter Impfstoff gegen Schweinepleuropneumonie | |
EP0324774A1 (de) | Klonierung und expression des treponema pallidum-47-kilodalton-antigens. | |
EP0564532B1 (de) | Von proteinen des hepatitis c-virus abgeleitete polypeptide und deren verwendung | |
DE3942728C1 (en) | New immunologically active proteins derived from Borelia burgdorferiensity polyethylene vessel and a high density polyethylene sealing cap - useful as vaccine and for quick accurate diagnosis of Borelia infections | |
DE4002636A1 (de) | Expression von hiv1- und 2-polypeptiden und deren verwendung | |
EP0893504A1 (de) | Von Kaposi-sarkom assoziiertem Herpes-Virus (KSHV, HHV-8) kodiertes Polypeptid und dessen Verwendung in Diagnostik und Therapie | |
DE19650758C1 (de) | PKD1-Fragmente mit Bindungsregionen für PKD1-spezifische Antikörper | |
DE60216958T2 (de) | Eine den gp41-zwischenzustand imitierende struktur bildendes polypeptid-antigen | |
DE4018988C2 (de) | Immunologisch aktive Proteine von Borrelia burgdorferi, Testkits, die diese Proteine enthalten und zum Nachweis von Antikörpern in Untersuchungsflüssigkeiten geeignet sind, monoklonale Antikörper, die gegen die immunologisch aktiven Proteine gerichtet sind und die Verwendung dieser Proteine als Impfstoffe gegen durch Borrelia-Stämme hervorgerufene Infektionen | |
EP0434992A1 (de) | Enterovirale Polypeptide und gruppenspezifischer Nachweis von Enterovirusinfektionen | |
EP0305777A2 (de) | Herstellung von Antigenen des Human Immunodeficiency Virus Typ 1 sowie deren Verwendung als diagnostisches Mittel und Therapeutikum | |
DE4419294A1 (de) | Ein 29 kD großes Membranprotein von Legionella pneumophila sowie dessen Nukleinsäuresequenz und die Verwendung in Diagnostik und Therapie |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1997935563 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2263152 Country of ref document: CA Ref country code: CA Ref document number: 2263152 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09242299 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1997935563 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 1998509349 Format of ref document f/p: F |
|
WWG | Wipo information: grant in national office |
Ref document number: 1997935563 Country of ref document: EP |